Lorlatinib (DB12130): A Comprehensive Monograph on a Third-Generation ALK/ROS1 Tyrosine Kinase Inhibitor

Executive Summary

Lorlatinib represents a paradigm shift in the management of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Developed by Pfizer, it is a third-generation, central nervous system (CNS)-penetrant, macrocyclic tyrosine kinase inhibitor (TKI) designed to target both ALK and ROS1 oncogenic drivers.[1] Its clinical development was predicated on overcoming the primary limitations of earlier-generation ALK inhibitors: acquired resistance and inadequate control of CNS metastases. The landmark Phase 3 CROWN trial has established lorlatinib as a superior first-line treatment for ALK-positive NSCLC, demonstrating an unprecedented 5-year progression-free survival (PFS) rate of 60%, a result that fundamentally redefines the long-term prognosis for this patient population.[3]

A defining feature of lorlatinib is its profound and durable intracranial activity. The drug was specifically engineered to cross the blood-brain barrier, and clinical data confirm its exceptional ability to not only induce high response rates in patients with existing brain metastases but also to provide a robust protective effect against the development of new CNS lesions.[6] This attribute addresses a critical unmet need, as the brain is a common and challenging site of disease progression in ALK-positive NSCLC.

The therapeutic benefits of lorlatinib are accompanied by a unique and manageable safety profile, characterized primarily by on-target effects such as hyperlipidemia and a spectrum of CNS adverse events, including cognitive and mood changes.[9] These toxicities are distinct from those of earlier-generation TKIs and necessitate proactive monitoring and management, often through dose modifications that have been shown not to compromise efficacy.[3]

In the context of acquired resistance, lorlatinib plays a dual role. It is highly effective in overcoming a broad spectrum of resistance mutations that confer resistance to first- and second-generation ALK inhibitors, including the highly refractory G1202R mutation.[12] However, tumors can develop acquired resistance to lorlatinib, primarily through the emergence of complex compound ALK mutations when used in later lines of therapy, or via ALK-independent bypass pathway activation when used as a first-line agent.[14]

Collectively, the compelling body of evidence from pivotal clinical trials has solidified lorlatinib's position as a preferred first-line standard-of-care in major international treatment guidelines, setting a new benchmark for efficacy in molecularly targeted cancer therapy.[16]

Drug Profile and Chemical Characteristics

Lorlatinib is classified as a small molecule kinase inhibitor, developed to function as a potent antineoplastic agent.[1] Its identity is defined by a specific set of nomenclature, chemical identifiers, and a unique structural architecture that is fundamental to its pharmacological activity.

Nomenclature and Identification

The universally recognized generic name for the compound is lorlatinib.[6] Commercially, it is marketed under the brand name

Lorbrena in the United States, Canada, and Japan, and as Lorviqua in the European Union.[1] During its development phase, it was identified by the code name PF-06463922.[6]

For scientific and regulatory tracking, lorlatinib is assigned numerous unique identifiers. Its DrugBank Accession Number is DB12130, and its Chemical Abstracts Service (CAS) Registry Number is 1454846-35-5.[1] Other significant identifiers include the FDA Unique Ingredient Identifier (UNII) OSP71S83EU, European Community (EC) Number 813-704-5, and ChEBI ID CHEBI:143117, among others cataloged in databases such as ChEMBL, KEGG, and PharmGKB.[1]

Chemical Structure and Properties

Lorlatinib possesses the molecular formula C21​H19​FN6​O2​ and a formula weight of approximately 406.4 g/mol.[20] Its formal IUPAC name is (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.0$^{2,6}

.0^{10,15}$]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile.[1]

Structurally, lorlatinib is a complex organic heterotetracyclic compound. It is classified as an azamacrocycle and incorporates several key functional groups and structural motifs, including a pyrazole ring, a monofluorobenzene moiety, an aromatic ether, a nitrile group, a benzamide, an aminopyridine, and a cyclic ether.[1] Physically, it is a crystalline solid with defined solubility in various laboratory solvents, including dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and ethanol.[21]

The macrocyclic (azamacrocycle) architecture of lorlatinib is a deliberate and critical element of its design, distinguishing it from the more flexible, linear structures of first- and second-generation ALK inhibitors like crizotinib and alectinib. This specific structural feature is directly responsible for its unique and superior pharmacological profile. Acquired resistance mutations, particularly the G1202R "solvent front" mutation, induce conformational changes in the ATP-binding pocket of the ALK kinase domain. These changes create steric hindrance that prevents the effective binding of larger, more flexible linear inhibitors.[12] Lorlatinib's compact and conformationally rigid macrocyclic structure, however, allows it to fit within this sterically constrained binding pocket, thereby overcoming this critical mechanism of resistance.[1] Furthermore, the physicochemical properties conferred by this unique structure are thought to be instrumental in facilitating its efficient penetration of the blood-brain barrier, addressing the clinical challenge of CNS metastases.[6] Thus, the azamacrocycle structure is the direct molecular basis for lorlatinib's two most significant clinical advantages: its broad activity against resistance mutations and its potent CNS efficacy. This represents a clear success in rational drug design, where a specific chemical architecture was engineered to solve known clinical challenges.

Table 1: Chemical and Physical Properties of Lorlatinib

Property	Value	Source Snippet(s)
Generic Name	lorlatinib	6
Brand Names	Lorbrena (US, CA, JP); Lorviqua (EU)	1
Developmental Code	PF-06463922	6
DrugBank ID	DB12130	1
CAS Number	1454846-35-5	1
Molecular Formula	C21​H19​FN6​O2​	20
Formula Weight	406.4 g/mol	20
IUPAC Name	(16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.0$^{2,6}.0^{10,15}$]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile	1
InChIKey	IIXWYSCJSQVBQM-LLVKDONJSA-N	1
SMILES	C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C	1
Structural Class	Azamacrocycle, Pyrazole, Nitrile, Benzamide	1
Physical Form	Crystalline solid	21
Solubility	DMF: 5 mg/mL; DMSO: 5 mg/mL; Ethanol: 1 mg/mL	21

Preclinical and Clinical Pharmacology

The pharmacological profile of lorlatinib is defined by its potent mechanism of action as a multi-kinase inhibitor, its favorable pharmacokinetic properties that support once-daily oral dosing, and its predictable pharmacodynamic effects on cardiac electrophysiology and other systemic parameters.

Mechanism of Action

Lorlatinib functions as a highly selective, reversible, and ATP-competitive small molecule inhibitor of ALK and ROS1 receptor tyrosine kinases (EC 2.7.10.1).[1] These kinases, when constitutively activated by chromosomal rearrangements (e.g., EML4-ALK), become potent oncogenic drivers that promote uncontrolled cell division and tumor growth.[23] Lorlatinib exerts its antineoplastic effect by binding with high affinity to the ATP-binding pocket within the ALK tyrosine kinase domain. This action inhibits the enzyme's autophosphorylation and blocks the subsequent activation of critical downstream signaling cascades, including the RAS-MAPK, PI3K-AKT, and JAK-STAT pathways, ultimately leading to the suppression of cancer cell proliferation and survival.[23]

The potency of lorlatinib is exceptional, with preclinical studies demonstrating very low inhibitor constant (Ki​) values: <0.07 nM for wild-type ALK and <0.025 nM for ROS1.[19] It also maintains high potency against ALK enzymes harboring resistance mutations, such as ALK$^{L1196M}$ (

Ki​ = 0.7 nM).[19] Furthermore, lorlatinib exhibits remarkable selectivity, being over 100-fold more selective for ALK/ROS1 compared to a broad panel of 204 other kinases, minimizing off-target activity.[22]

While ALK and ROS1 are its primary targets, in vitro assays have shown that lorlatinib also possesses inhibitory activity against a number of other tyrosine kinases, including TYK1, FER, FPS, the TRK family (TRKA, TRKB, TRKC), FAK, FAK2, and ACK.[6] The clinical significance of this broader kinase profile is not fully elucidated. Inhibition of kinases like FAK, which is involved in cell migration and invasion, could theoretically contribute to its anti-metastatic effects. Conversely, this polypharmacology may also contribute to its unique toxicity profile. For instance, the inhibition of TRKB and TRKC, which are vital for neuronal function, could potentially be linked to the observed CNS adverse effects. This represents an area for future translational research to dissect the specific contributions of each inhibited kinase to the overall clinical phenotype of efficacy and toxicity.

A cornerstone of lorlatinib's design and a key differentiator from earlier-generation TKIs is its ability to efficiently penetrate the blood-brain barrier.[7] This property allows it to achieve and maintain therapeutic concentrations within the CNS, enabling it to effectively treat and prevent brain metastases, a common sanctuary site and cause of morbidity in patients with ALK-positive NSCLC.[6]

Pharmacokinetics

The pharmacokinetic properties of lorlatinib have been well-characterized, defining its absorption, distribution, metabolism, and excretion (ADME) profile. At the recommended dose of 100 mg once daily, lorlatinib reaches a mean maximum plasma concentration (Cmax​) of 577 ng/mL and an area under the curve over 24 hours (AUC0−24h​) of 5650 ng·h/mL in cancer patients.[10]

Absorption

Lorlatinib is rapidly absorbed following oral administration, with a median time to maximum plasma concentration (Tmax​) of 1.2 hours after a single dose and 2 hours at steady state.[6] It exhibits high oral bioavailability, with a mean absolute bioavailability of 81% compared to intravenous administration.[6] The administration of lorlatinib with a high-fat, high-calorie meal does not produce a clinically meaningful effect on its pharmacokinetics, allowing it to be taken with or without food.[9]

Distribution

Lorlatinib demonstrates extensive distribution into tissues, as indicated by a large mean steady-state volume of distribution (Vss​) of 305 L.[10] It is moderately bound (66%) to human plasma proteins, primarily albumin and α1-acid glycoprotein.[9]

Metabolism and Elimination

The mean plasma half-life (t1/2​) of lorlatinib is approximately 24 hours after a single 100 mg dose, which supports a once-daily dosing regimen.[10] Elimination occurs through extensive metabolism followed by excretion in both urine and feces. After a single radiolabeled dose, 48% of the radioactivity was recovered in urine (<1% as unchanged drug) and 41% in feces (~9% as unchanged drug).[9]

Metabolism is the primary route of clearance, mediated predominantly by the cytochrome P450 enzyme CYP3A4 and the UDP-glucuronosyltransferase UGT1A4.[9] This heavy reliance on CYP3A4 makes lorlatinib highly susceptible to clinically significant drug-drug interactions.[23] The major circulating metabolite, M8 (a benzoic acid derivative formed via cleavage of the amide and ether bonds), is pharmacologically inactive.[10]

A critical pharmacokinetic feature of lorlatinib is its capacity for autoinduction. Lorlatinib is a time-dependent inducer of CYP3A, leading to an increase in its own metabolism over time.[1] This is evidenced by an increase in its mean oral clearance (CL/F) from 11 L/h after a single dose to 18 L/h at steady state.[10] This property implies that steady-state drug concentrations are lower than what might be predicted from single-dose data. Furthermore, as a CYP3A inducer, lorlatinib can act as a perpetrator in drug-drug interactions, potentially reducing the plasma concentrations and efficacy of co-administered medications that are CYP3A substrates. This dual role as both a substrate and an inducer of CYP3A complicates its clinical pharmacology and necessitates careful review of concomitant medications.

Specific Populations

No clinically significant dose adjustments are required based on age, sex, race, body weight, mild-to-moderate renal impairment, or mild hepatic impairment.[6] However, in patients with severe renal impairment (creatinine clearance [CLcr] 15 to <30 mL/min), lorlatinib exposure (

AUCinf​) is increased by 42%, necessitating a dose reduction.[10] The pharmacokinetics in patients with moderate-to-severe hepatic impairment or end-stage renal disease have not been established.[29]

Pharmacodynamics

The pharmacodynamic effects of lorlatinib are directly related to its plasma exposure. A clear exposure-response relationship has been established for both efficacy and safety. Higher steady-state concentrations of lorlatinib are associated with a greater probability of tumor response but also with an increased likelihood of experiencing Grade 3 or 4 adverse reactions, particularly hypercholesterolemia.[10]

In terms of cardiac electrophysiology, lorlatinib has been shown to cause concentration-dependent prolongation of the PR interval. In clinical studies, 14% of patients with a normal baseline PR interval experienced prolongation, and atrioventricular (AV) block occurred in 1.9% of patients.[9] A rare case (0.2%) of Grade 3 AV block required pacemaker implantation.[9] Importantly, no large mean increases in the corrected QT (QTc) interval have been detected, indicating a low risk for Torsades de Pointes.[10]

Clinical Efficacy in ALK-Positive Non-Small Cell Lung Cancer

The clinical development of lorlatinib has robustly demonstrated its efficacy across the spectrum of ALK-positive NSCLC, from heavily pre-treated patients with acquired resistance to the first-line setting. Its approval and integration into clinical practice are supported by data from a pivotal Phase 2 study and the landmark Phase 3 CROWN trial.

Efficacy in Previously Treated NSCLC (Phase 2 Study B7461001)

The initial accelerated approvals for lorlatinib were based on the results of Study B7461001 (NCT01970865), a global, multicenter, non-randomized, Phase 2 trial.[2] This study enrolled patients with advanced ALK-positive or ROS1-positive NSCLC into distinct cohorts based on their prior treatment history, allowing for a detailed assessment of lorlatinib's activity in various resistance settings.[33]

In the pooled cohort of 198 ALK-positive patients who had received at least one prior ALK TKI, the overall objective response rate (ORR), as assessed by an independent central review (ICR), was 47.0%.[31] The efficacy varied significantly depending on the specific treatment history, providing a clinical reflection of the molecular evolution of resistance.

• Post-Crizotinib Only: In 59 patients whose only prior ALK TKI was the first-generation inhibitor crizotinib, the ORR was 69.5%. This high response rate suggests that resistance to crizotinib is often driven by on-target ALK mutations that remain highly sensitive to the potent inhibition by lorlatinib.[31]
• Post-One Second-Generation TKI: In 28 patients who had progressed on a single second-generation TKI (e.g., alectinib, ceritinib), the ORR was 32.1%.[31]
• Post-Two or More TKIs: In a heavily pre-treated cohort of 111 patients who had failed two or more prior ALK TKIs, the ORR was 38.7%.[31]

The more modest, though still clinically meaningful, response rates in patients refractory to second-generation TKIs indicate a more complex resistance landscape in this population. Resistance in these cases can be driven not only by ALK mutations that lorlatinib can inhibit but also by ALK-independent bypass pathway activation or the emergence of complex compound mutations, which may not be susceptible to lorlatinib monotherapy.12

The study also confirmed lorlatinib's potent intracranial activity. Among ALK-positive patients with measurable baseline CNS lesions, the intracranial ORR (IC-ORR) was 63.0% overall.[31] The IC-ORR was highest in the post-crizotinib cohort at 87.0% and remained substantial in patients who had progressed on one (55.6%) or more (53.1%) second-generation TKIs.[34]

In a separate cohort of patients with ROS1-positive NSCLC, lorlatinib also demonstrated activity. The ORR was 36% in a mixed population of TKI-naïve and pre-treated patients.[35] A more detailed analysis showed an ORR of 62% in TKI-naïve patients (median PFS of 21.0 months) and 35% in patients pre-treated with a prior TKI (median PFS of 8.5 months).[36]

Efficacy in First-Line Treatment (Phase 3 CROWN Study)

The role of lorlatinib in the first-line setting was definitively established by the Phase 3 CROWN trial (NCT03052608), an open-label, randomized, active-controlled study.[37] The trial compared lorlatinib monotherapy (100 mg once daily) against the first-generation inhibitor crizotinib (250 mg twice daily) in 296 treatment-naïve patients with advanced ALK-positive NSCLC.[39] The results from this trial have set a new benchmark for efficacy in this disease.

Progression-Free Survival

The primary endpoint of the CROWN trial was PFS, assessed by blinded independent central review (BICR).

• Initial Analysis: At a planned interim analysis with a median follow-up of 18.3 months, lorlatinib demonstrated a statistically significant and clinically profound improvement in PFS, reducing the risk of disease progression or death by 72% compared to crizotinib (Hazard Ratio 0.28; 95% Confidence Interval [CI], 0.19 to 0.41; p<0.001). The 12-month PFS rate was 78% for lorlatinib versus 39% for crizotinib.[39]
• 5-Year Follow-up: Long-term follow-up data presented after a median of approximately 60 months confirmed and extended these remarkable findings. The median PFS for patients in the lorlatinib arm had still not been reached, while it was 9.1 months for the crizotinib arm (HR 0.19; 95% CI, 0.13 to 0.27).[4] The 5-year PFS rate was an unprecedented 60% for patients treated with lorlatinib, compared to just 8% for those treated with crizotinib.[3]

These PFS results are the longest ever reported for any single-agent molecularly targeted therapy in advanced NSCLC and across metastatic solid tumors, fundamentally altering the expected disease trajectory for newly diagnosed patients.[3] This level of durable disease control suggests that for a majority of patients, ALK-positive NSCLC can be managed as a chronic condition, shifting the clinical focus from managing imminent progression to maintaining long-term quality of life and mitigating chronic toxicities.

Overall and Intracranial Response

Lorlatinib also demonstrated superior response rates compared to crizotinib. The confirmed ORR was 76% in the lorlatinib arm versus 58% in the crizotinib arm.[7]

The intracranial efficacy of lorlatinib was particularly striking.

• Response in Baseline CNS Metastases: Among patients with measurable CNS lesions at baseline, the IC-ORR was 82% with lorlatinib (including a 71% complete intracranial response rate) versus 23% with crizotinib.[7] The duration of this intracranial response was highly durable, lasting 12 months or longer in 79% of lorlatinib responders, compared to 0% of crizotinib responders.[37]
• Prevention of CNS Progression: Lorlatinib exhibited a powerful protective effect against CNS progression. The median time to intracranial progression was not reached with lorlatinib, compared to 16.4 months with crizotinib (HR 0.06; 95% CI, 0.03 to 0.12).[4] In patients who entered the trial without brain metastases, only 4 of 114 (3.5%) developed CNS lesions while on lorlatinib, in stark contrast to 39 of 109 (35.8%) patients in the crizotinib arm.[3] After 5 years, 92% of all patients in the lorlatinib arm remained free of intracranial progression.[44]

Table 2: Summary of Efficacy Outcomes from the Phase 3 CROWN Trial (5-Year Follow-up)

Efficacy Endpoint	Lorlatinib (n=149)	Crizotinib (n=147)	Hazard Ratio (95% CI) / p-value	Source Snippet(s)
Median PFS (Investigator)	Not Reached	9.1 months	0.19 (0.13 - 0.27)	4
5-Year PFS Rate	60% (51 - 68)	8% (3 - 14)	N/A	3
Overall Response Rate (ORR)	76% (68 - 83)	58% (49 - 66)	N/A	7
Median Time to Intracranial Progression	Not Reached	16.4 months	0.06 (0.03 - 0.12)	4
Intracranial ORR (Baseline CNS Mets)	82% (57 - 96)	23% (5 - 54)	N/A	37
5-Year Freedom from Intracranial Progression	92%	21%	N/A	44

Safety, Tolerability, and Risk Management

The safety profile of lorlatinib is well-defined and distinct from that of earlier-generation ALK inhibitors. While generally manageable, it is characterized by a high incidence of specific on-target toxicities, particularly hyperlipidemia and a range of CNS effects, which require proactive monitoring and management to ensure patients can derive long-term benefit from the therapy.

Common and Significant Adverse Reactions

In a pooled safety population of 476 patients receiving the standard 100 mg daily dose, the most frequently reported adverse reactions (AEs) occurring in ≥20% of patients were edema (56%), peripheral neuropathy (44%), weight gain (31%), cognitive effects (28%), fatigue (27%), dyspnea (27%), arthralgia (24%), diarrhea (23%), mood effects (21%), and cough (21%).[29]

The hallmark toxicities of lorlatinib are:

• Hyperlipidemia: This is the most common laboratory abnormality, with Grade 3-4 hypercholesterolemia occurring in 16-18% of patients and Grade 3-4 hypertriglyceridemia in 16-19%.[5] The onset is typically rapid, with a median time of 15 days.[9] This AE is manageable with the initiation or dose escalation of lipid-lowering medications, which were required in 83% of patients, and with dose modifications of lorlatinib.[9]
• Central Nervous System (CNS) Effects: A broad spectrum of CNS effects is a notable feature of lorlatinib therapy, occurring in 52% of patients overall.[29] These effects are generally mild to moderate and reversible upon dose modification. The median time to first onset is 1.4 months.[9] The most common categories include:
• Cognitive Effects: 28% incidence (2.9% Grade 3-4), encompassing issues with memory, attention, and concentration ("brain fog").[5]
• Mood Effects: 21% incidence (1.7% Grade 3-4), including anxiety, depression, and irritability. Suicidal ideation has been reported.[29]
• Speech Effects: 11% incidence (0.6% Grade 3-4), such as dysarthria or slowed speech.[29]
• Psychotic Effects: 7% incidence (0.6% Grade 3-4), including hallucinations.[29]
• Seizures: Occurred in 1.9% of patients.[29]

Other clinically significant, though less frequent, severe AEs include:

• Atrioventricular (AV) Block: Resulting from PR interval prolongation, AV block was observed in 1.9% of patients. Grade 3 AV block is rare (0.2%) but may necessitate pacemaker placement.[9]
• Interstitial Lung Disease (ILD)/Pneumonitis: A serious pulmonary risk, occurring in 1.9% of patients (0.6% Grade 3-4). Any suspected treatment-related ILD/pneumonitis requires immediate and permanent discontinuation of the drug.[10]
• Hypertension: Occurred in 13% of patients, with 6% experiencing Grade 3-4 events. Blood pressure must be controlled prior to initiation and monitored regularly.[5]
• Hyperglycemia: Observed in 9% of patients (3.2% Grade 3-4), requiring baseline and periodic fasting glucose monitoring.[9]

The safety profile of lorlatinib appears to be a direct consequence of its potent, CNS-penetrant mechanism. The on-target inhibition of ALK signaling in normal tissues is believed to mediate the hyperlipidemia, while the high drug concentrations in the brain, essential for its intracranial efficacy, are inextricably linked to the spectrum of CNS AEs. This represents a therapeutic trade-off that is central to its clinical use, requiring a continuous balance between maximizing efficacy and mitigating predictable, mechanism-based toxicities.

Table 3: Incidence of Common (≥20%) and Grade 3-4 Adverse Reactions with Lorlatinib (CROWN Trial Data)

Adverse Reaction	Lorlatinib (Any Grade %)	Lorlatinib (Grade 3-4 %)	Crizotinib (Any Grade %)	Crizotinib (Grade 3-4 %)	Source Snippet(s)
Hypercholesterolemia	70%	16%	4%	0%	46
Hypertriglyceridemia	64%	20%	6%	0%	46
Edema	55%	1%	39%	<1%	46
Weight Gain	38%	17%	12%	2%	46
Peripheral Neuropathy	34%	2%	15%	<1%	46
Cognitive Effects	21%	2%	6%	0%	46
Hypertension	18%	10%	2%	1%	46
Diarrhea	21%	1%	52%	2%	46
Arthralgia	24%	1%	19%	<1%	29
Fatigue	19%	1%	32%	2%	46
Dyspnea	27%	3%	24%	3%	29

Contraindications and Drug-Drug Interactions

The clinical use of lorlatinib is governed by a critical contraindication and several important drug-drug interaction considerations, primarily related to its metabolism by CYP3A4.

• Contraindication: Co-administration of lorlatinib with strong inducers of CYP3A (e.g., rifampin, carbamazepine, phenytoin, St. John’s Wort) is contraindicated. This is due to a well-documented risk of severe, rapid-onset hepatotoxicity. In a drug-interaction study, this combination led to Grade 3 or 4 ALT/AST elevations in 83% of healthy subjects within days of co-administration.[10] Strong CYP3A inducers must be discontinued for at least 3 plasma half-lives before initiating lorlatinib.[45]
• Drug Interactions:
• Moderate CYP3A Inducers: Concomitant use should be avoided. If unavoidable, the daily dose of lorlatinib should be increased from 100 mg to 125 mg to compensate for the increased clearance.[10]
• Strong CYP3A Inhibitors and Fluconazole: These agents (e.g., ketoconazole, itraconazole, clarithromycin) can significantly increase lorlatinib plasma concentrations, raising the risk of toxicity. Concomitant use should be avoided. If necessary, the daily lorlatinib dose should be reduced from 100 mg to 75 mg.[23]
• CYP3A and P-gp Substrates: Lorlatinib itself is a moderate inducer of CYP3A and an inducer of P-glycoprotein (P-gp).[1] Therefore, it can decrease the plasma concentrations and potential efficacy of co-administered drugs that are substrates of these pathways. Concomitant use with sensitive substrates should be avoided.[29]
• Contraception: Because lorlatinib can induce metabolizing enzymes, it may render hormonal contraceptives ineffective. Female patients of reproductive potential must be advised to use an effective non-hormonal method of contraception during treatment and for at least 6 months after the final dose. Male patients with female partners of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose.[6]

Management of Adverse Events

Proactive management of adverse events is crucial for maintaining patients on lorlatinib therapy long-term. The cornerstone of this management is a clearly defined dose modification strategy.

• Dose Reduction Schedule: Based on individual safety and tolerability, the dose of lorlatinib can be reduced in a stepwise manner: the standard starting dose is 100 mg once daily, the first dose reduction is to 75 mg once daily, and the second dose reduction is to 50 mg once daily. If a patient is unable to tolerate the 50 mg daily dose, lorlatinib should be permanently discontinued.[10]
• Impact of Dose Reduction on Efficacy: A critical post-hoc analysis of the CROWN study demonstrated that dose reductions, even within the first 16 weeks of therapy, did not negatively impact PFS or time to intracranial progression.[3] This finding is of paramount clinical importance, as it empowers clinicians to manage toxicity aggressively through dose modification without fear of compromising the long-term efficacy of the treatment. It underscores that maintaining a tolerable dose is superior to discontinuing a highly effective therapy.

Table 4: Recommended Dose Modifications for Key Adverse Reactions

Adverse Reaction	Severity (Grade)	Recommended Action	Source Snippet(s)
Central Nervous System Effects	Grade 2 or 3	Withhold until ≤Grade 1. Resume at a reduced dose.	10
	Grade 4	Permanently discontinue.	10
Hyperlipidemia	Grade 4	Withhold until ≤Grade 2. Resume at the same dose. Initiate/increase lipid-lowering agents.	10
Atrioventricular (AV) Block	Second-degree	Withhold until PR interval <200 ms. Resume at a reduced dose. If pacemaker placed, resume at same dose.	10
	Third-degree	Withhold until PR interval <200 ms. Resume at a reduced dose. Permanently discontinue for recurrence.	10
Interstitial Lung Disease (ILD)/Pneumonitis	Any Grade (treatment-related)	Permanently discontinue.	10
Hypertension	Grade 3	Withhold until ≤Grade 1. Resume at the same dose. If recurs, withhold and resume at reduced dose.	10
	Grade 4	Withhold until ≤Grade 1. Resume at a reduced dose or permanently discontinue.	10
Hyperglycemia	Grade 3 or 4	Withhold until normoglycemic. Resume at a reduced dose.	10

Mechanisms of Resistance

The clinical utility of lorlatinib is defined by its interaction with the mechanisms of drug resistance in ALK-positive NSCLC. It was developed to overcome established resistance to prior-generation TKIs, yet its use creates new selective pressures that lead to the evolution of novel resistance mechanisms.

Overcoming Resistance to Prior-Generation TKIs

Lorlatinib was specifically engineered to address the primary cause of treatment failure with first- and second-generation ALK inhibitors: the emergence of on-target secondary mutations within the ALK kinase domain.[9]

• Broad Mutational Coverage: Preclinical studies confirmed that lorlatinib retains potent inhibitory activity against the vast majority of single ALK resistance mutations identified in patients progressing on crizotinib, alectinib, ceritinib, and brigatinib.[6] Its unique macrocyclic structure allows it to bind effectively to the mutated ALK enzyme where other inhibitors fail.[1]
• Activity Against G1202R: A key advantage of lorlatinib is its robust activity against the highly refractory G1202R solvent-front mutation. This mutation accounts for a significant proportion of resistance cases following second-generation TKI therapy and confers high-level resistance to all second-generation agents.[12] Lorlatinib is the first approved TKI to demonstrate potent clinical activity against tumors harboring this mutation.
• Clinical Validation: The link between ALK mutation status and lorlatinib efficacy was validated in a planned molecular analysis of the Phase 2 trial.[13] In patients who had failed one or more second-generation ALK TKIs, the ORR was significantly higher among those with a detectable baseline ALK mutation (69% via tissue genotyping) compared to those without (27%). This finding suggests that tumors acquiring on-target ALK resistance mutations remain "ALK-addicted" and are therefore highly sensitive to a more potent and broadly active inhibitor like lorlatinib.

Acquired Resistance to Lorlatinib

Despite its potency, acquired resistance to lorlatinib inevitably develops. The mechanisms of this resistance are fundamentally dependent on the line of therapy in which lorlatinib is used, reflecting the principles of cancer evolution under therapeutic pressure.

• On-Target Resistance: Compound Mutations: When lorlatinib is administered in later lines of therapy (i.e., after a patient has already progressed on one or more other ALK TKIs), the predominant mechanism of on-target resistance is the emergence of compound mutations. These are defined as the presence of two or more distinct resistance mutations on the same ALK allele.[12] The sequential use of ALK inhibitors fosters this stepwise accumulation of mutations. A tumor may first acquire a mutation (e.g., I1171N) that confers resistance to a second-generation TKI. When lorlatinib is then introduced, it effectively inhibits this single mutant, but this creates a new selective pressure that can lead to the acquisition of a second mutation (e.g., G1202R) on the same allele, resulting in a highly resistant G1202R/I1171N compound mutant.[12] These complex mutations can confer high-level resistance to all currently available ALK inhibitors, highlighting the need for the development of fourth-generation TKIs.[12]
• Off-Target Resistance: Bypass Pathways: In the first-line setting, where lorlatinib's broad activity effectively prevents the emergence of single ALK resistance mutations, a different resistance mechanism predominates. Analysis of circulating tumor DNA from patients progressing on first-line lorlatinib in the CROWN trial did not detect the emergence of new ALK resistance mutations.[8] This suggests that resistance in the TKI-naïve setting is primarily driven by ALK-independent mechanisms, such as the activation of alternative signaling or "bypass" pathways.[15] These can include the amplification of or mutations in other oncogenes like MET or NRAS.[15] This scenario presents a different clinical challenge, where the next line of therapy may need to target the newly activated pathway rather than ALK itself.
• Paradoxical Re-sensitization: An interesting and clinically relevant phenomenon has been observed where certain compound mutations (specifically those involving the L1198F mutation) can paradoxically re-sensitize the tumor to the first-generation inhibitor, crizotinib.[15] This underscores the importance of re-biopsy and comprehensive molecular profiling at the time of progression to guide subsequent treatment decisions.

The pattern of resistance to lorlatinib illustrates a critical strategic consideration in oncology. Using the most potent agent, lorlatinib, in the first-line setting provides the longest duration of disease control and may prevent the formation of complex ALK mutations. However, when resistance eventually occurs, it is likely to be ALK-independent. Conversely, using lorlatinib in later lines targets known ALK resistance mutations but drives the selection of highly resistant compound mutations. The unprecedented long-term PFS data from the CROWN trial provide compelling evidence in favor of the first-line strategy to maximize patient benefit.

Regulatory and Therapeutic Landscape

Lorlatinib has undergone a rapid and successful global regulatory journey, transitioning from an agent for pre-treated patients to a first-line standard of care. Its position in the therapeutic landscape is defined by its regulatory approvals, its standing in clinical practice guidelines, and its comparative profile against other next-generation ALK inhibitors.

Regulatory Approval History

Lorlatinib's path to approval was expedited by regulatory designations recognizing its potential to address a significant unmet medical need.

• U.S. Food and Drug Administration (FDA): Marketed as Lorbrena, lorlatinib received Breakthrough Therapy and Orphan Drug designations.[2]
• November 2, 2018: The FDA granted Accelerated Approval for the treatment of adult patients with ALK-positive metastatic NSCLC whose disease had progressed on crizotinib and at least one other ALK inhibitor, or on alectinib or ceritinib as first-line ALK inhibitor therapy. This approval was based on the compelling ORR and duration of response data from the Phase 2 Study B7461001.[2]
• March 3, 2021: Following the positive results of the CROWN trial, the FDA granted full, regular approval to lorlatinib and expanded its indication to include the first-line treatment of adults with ALK-positive metastatic NSCLC. This action converted the prior accelerated approval to a full approval.[37]
• European Medicines Agency (EMA): Marketed as Lorviqua, the approval process followed a similar trajectory.
• May 6, 2019: The European Commission granted a Conditional Marketing Authorisation for lorlatinib as a monotherapy for adult patients with ALK-positive advanced NSCLC whose disease had progressed after specific prior ALK TKI therapies.[18]
• January 28, 2022: The indication was extended to include the first-line treatment of adult patients with ALK-positive advanced NSCLC, based on the CROWN trial data.[43]

Table 5: Key Regulatory Approval Milestones for Lorlatinib

Regulatory Agency	Date	Action / Indication	Basis for Approval (Trial)	Source Snippet(s)
FDA (US)	Nov 2, 2018	Accelerated Approval for 2nd/3rd-line treatment	Phase 2 Study B7461001	32
FDA (US)	Mar 3, 2021	Full Approval for 1st-line treatment	Phase 3 CROWN Study	37
EMA (EU)	May 6, 2019	Conditional Authorisation for 2nd/3rd-line treatment	Phase 2 Study B7461001	18
EMA (EU)	Jan 28, 2022	Full Approval for 1st-line treatment	Phase 3 CROWN Study	43

Comparative Analysis and Position in Clinical Guidelines

With several highly effective next-generation ALK inhibitors available, the choice of first-line therapy is a key clinical question. While no head-to-head Phase 3 trials have directly compared lorlatinib to second-generation agents like alectinib or brigatinib, a substantial body of evidence from indirect comparisons and network meta-analyses (NMAs) informs its position.[57]

• Comparative Efficacy:
• Multiple NMAs of first-line trials consistently suggest that lorlatinib provides the greatest PFS benefit compared to all other ALK TKIs, including alectinib and brigatinib.[59] The superiority of lorlatinib in prolonging PFS appears most pronounced in patients with baseline CNS metastases.[59]
• While most analyses favor lorlatinib on PFS, overall survival (OS) data for all next-generation TKIs remain immature, making definitive conclusions on OS difficult. Some analyses suggest alectinib may have a favorable OS trend, though this is not conclusive.[61]
• Comparative Safety:
• Lorlatinib is associated with a higher incidence of Grade 3-4 adverse events compared to alectinib, a difference driven almost entirely by the high rates of manageable hyperlipidemia.[39]
• Conversely, indirect comparisons suggest that the rate of permanent treatment discontinuation due to adverse events may be lower with lorlatinib (7%) than with alectinib (~11-26%).[39]
• Position in Clinical Guidelines:
• Based on the strength of the CROWN trial data, major clinical practice guidelines, including those from the National Comprehensive Cancer Network (NCCN), recommend lorlatinib as a preferred Category 1 option for the first-line treatment of patients with ALK-positive metastatic NSCLC.[16] It shares this recommendation with alectinib and brigatinib.
• Lorlatinib also remains a critical treatment option for patients who have progressed on other ALK inhibitors, particularly those with CNS progression or known ALK resistance mutations.[16]

Conclusion and Future Perspectives

Lorlatinib has fundamentally transformed the therapeutic landscape for ALK-positive NSCLC. It stands as a testament to the success of rational drug design, having been specifically engineered to overcome the dual clinical challenges of acquired resistance and CNS disease progression that limited the efficacy of earlier-generation inhibitors. The unprecedented 5-year progression-free survival outcomes from the Phase 3 CROWN trial have not only established a new benchmark for efficacy in solid tumor oncology but have also shifted the treatment paradigm, making long-term, chronic disease management a realistic goal for the majority of newly diagnosed patients.

Currently, lorlatinib is firmly established as a preferred first-line standard of care, particularly for patients with, or at high risk of developing, brain metastases. Its optimal use, however, demands a nuanced understanding of its unique safety profile. The clinical management of a lorlatinib-treated patient requires a proactive and sustained focus on mitigating its predictable on-target toxicities, such as hyperlipidemia and CNS effects, through regular monitoring, supportive care, and judicious dose modifications.

Despite its profound impact, challenges remain. The primary obstacle on the horizon is the development of acquired resistance to lorlatinib itself. Future research efforts must be directed toward two key areas:

1. Overcoming Lorlatinib Resistance: The development of novel therapeutic strategies is imperative. This includes the investigation of rational combination therapies, such as pairing lorlatinib with inhibitors of bypass signaling pathways (e.g., MET inhibitors), to delay or treat off-target resistance.[51] Furthermore, there is an urgent need for the development of fourth-generation ALK TKIs specifically designed to inhibit the complex compound mutations that arise in the post-lorlatinib setting.[12]
2. Optimizing Long-Term Management: As patients live for many years on lorlatinib, a deeper understanding of the chronic, low-grade toxicities and their impact on long-term quality of life is essential. Research into refining toxicity management strategies and further personalizing dosing will be critical to ensuring that extended survival is accompanied by preserved well-being.

In conclusion, lorlatinib has redefined the possibilities of treatment for ALK-positive NSCLC. The focus of the field now shifts from establishing its efficacy to optimizing its long-term use and strategically planning for the inevitable challenge of subsequent resistance.

Works cited

1. Lorlatinib | C21H19FN6O2 | CID 71731823 - PubChem, accessed August 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lorlatinib
2. Lorlatinib - Wikipedia, accessed August 8, 2025, https://en.wikipedia.org/wiki/Lorlatinib
3. Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases, accessed August 8, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2024/lorlatinib-alk-positive-lung-cancer-initial-treatment
4. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/38819031/
5. Pfizer's LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression, accessed August 8, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizers-lorbrenar-crown-study-shows-majority-patients-alk
6. Lorlatinib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 8, 2025, https://go.drugbank.com/drugs/DB12130
7. How It Works | Lorbrena® (lorlatinib) Patient Site | Safety Info, accessed August 8, 2025, https://www.lorbrena.com/how-lorbrena-works
8. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study - ASCO Publications, accessed August 8, 2025, https://ascopubs.org/doi/10.1200/JCO.24.00581
9. lorlatinib | Cancer Care Ontario, accessed August 8, 2025, https://www.cancercareontario.ca/en/system/files_force/lorlatinib.pdf?download=1
10. This label may not be the latest approved by FDA. For current ..., accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf
11. Impact of lorlatinib dose modifications on adverse event outcomes in the phase 3 CROWN study. - ASCO, accessed August 8, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT483582
12. Analysis of lorlatinib analogs reveals a roadmap for targeting ..., accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9732888/
13. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer - PMC - PubMed Central, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6544460/
14. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant ..., accessed August 8, 2025, https://aacrjournals.org/cancerdiscovery/article/8/6/714/10113/Sequential-ALK-Inhibitors-Can-Select-for
15. Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial - Facchinetti, accessed August 8, 2025, https://cco.amegroups.org/article/view/21761/html
16. NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer, accessed August 8, 2025, https://www.nccn.org/patients/guidelines/content/PDF/lung-metastatic-patient.pdf
17. First-Line Treatment of ALK-Positive Metastatic NSCLC, accessed August 8, 2025, https://sponsored.harborsidestudio.com/first-line-treatment-of-alk-positive-metastatic-nsclc/?utm_source=TAP&utm_medium=Website&utm_campaign=TAP_HP
18. Lorviqua | European Medicines Agency (EMA), accessed August 8, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua
19. Lorlatinib (PF-06463922) | ALK/ROS1 Inhibitor | MedChemExpress, accessed August 8, 2025, https://www.medchemexpress.com/PF-06463922.html
20. Lorlatinib | CAS 1454846-35-5 | SCBT - Santa Cruz Biotechnology, accessed August 8, 2025, https://www.scbt.com/p/lorlatinib-1454846-35-5
21. PF-06463922 (Lorlatinib, CAS Number: 1454846-35-5) | Cayman Chemical, accessed August 8, 2025, https://www.caymanchem.com/product/18371/pf-06463922
22. PF 06463922 (CAS 1454846-35-5) - R&D Systems, accessed August 8, 2025, https://www.rndsystems.com/products/pf-06463922_5640
23. What is Lorlatinib used for? - Patsnap Synapse, accessed August 8, 2025, https://synapse.patsnap.com/article/what-is-lorlatinib-used-for
24. Lorlatinib | Pfizer, accessed August 8, 2025, https://cdn.pfizer.com/pfizercom/news/asco/Lorlatinib_Fact_Sheet.pdf
25. Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9917367/
26. PF 06463922 | CAS 1454846-35-5 | PF06463922 - Tocris Bioscience, accessed August 8, 2025, https://www.tocris.com/products/pf-06463922_5640
27. pubchem.ncbi.nlm.nih.gov, accessed August 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Lorlatinib#:~:text=7.7%20Mechanism%20of%20Action&text=Subsequnetly%2C%20lorlatinib%20is%20a%20kinase,FAK%2C%20FAK2%2C%20and%20ACK.
28. Annotation of FDA Label for lorlatinib and ROS1 - PharmGKB, accessed August 8, 2025, https://www.clinpgx.org/labelAnnotation/PA166182747
29. LORBRENA® (lorlatinib) Official HCP Website | Safety Info, accessed August 8, 2025, https://lorbrena.pfizerpro.com/
30. European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer | Pfizer, accessed August 8, 2025, https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_lorviqua_lorlatinib_for_certain_adult_patients_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer
31. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study | Request PDF - ResearchGate, accessed August 8, 2025, https://www.researchgate.net/publication/328785566_Lorlatinib_in_patients_with_ALK-positive_non-small-cell_lung_cancer_results_from_a_global_phase_2_study
32. FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC, accessed August 8, 2025, https://www.fda.gov/drugs/fda-approves-lorlatinib-second-or-third-line-treatment-alk-positive-metastatic-nsclc
33. Next-Generation ALK/ROS1 Inhibitor Lorlatinib Shows Strong, Durable Responses in Advanced NSCLC - The Oncology Nurse, accessed August 8, 2025, https://www.theoncologynurse.com/web-exclusives/next-generation-alk-ros1-inhibitor-lorlatinib-shows-strong-durable-responses-in-advanced-nsclc
34. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/30413378/
35. Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer, accessed August 8, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_full_results_from_phase_2_study_of_next_generation_investigational_alk_inhibitor_lorlatinib_in_alk_positive_and_ros1_positive_advanced_non_small_cell_lung_cancer
36. Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK ..., accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9576009/
37. FDA approves lorlatinib for metastatic ALK-positive NSCLC, accessed August 8, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc
38. Phase 3 CROWN Trial Shows Promise for Lorlatinib in Previously Untreated ALK-Positive NSCLC - CancerNetwork, accessed August 8, 2025, https://www.cancernetwork.com/view/phase-3-crown-trial-shows-promise-for-lorlatinib-in-previously-untreated-alk-positive-nsclc
39. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/33207094/
40. Results from Phase 3 CROWN Trial of Pfizer's LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine, accessed August 8, 2025, https://www.pfizer.com/news/press-release/press-release-detail/results-phase-3-crown-trial-pfizers-lorbrenar-lorlatinib
41. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study - ASCO Publications, accessed August 8, 2025, https://ascopubs.org/doi/pdf/10.1200/JCO.24.00581
42. CROWN Trial of Lorlatinib Offers Durable PFS in ALK+ Lung Cancer - Targeted Oncology, accessed August 8, 2025, https://www.targetedonc.com/view/crown-trial-of-lorlatinib-offers-durable-pfs-in-alk-lung-cancer
43. First-Line Lorlatinib Receives Approval From the European Commission for ALK+ Advanced NSCLC - CancerNetwork, accessed August 8, 2025, https://www.cancernetwork.com/view/first-line-lorlatinib-receives-approval-from-the-european-commission-for-alk-advanced-nsclc
44. Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC: 5-Year Outcomes From Phase III CROWN Trial - The ASCO Post, accessed August 8, 2025, https://ascopost.com/issues/august-25-2024/lorlatinib-vs-crizotinib-in-advanced-alk-positive-nsclc-5-year-outcomes-from-phase-iii-crown-trial/
45. LORBRENA (lorlatinib) - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf
46. From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) - MDPI, accessed August 8, 2025, https://www.mdpi.com/2075-4418/14/1/48
47. Lorviqua, INN-lorlatinib - EMA, accessed August 8, 2025, https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf
48. Pfizer's Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer | Pfizer, accessed August 8, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_next_generation_alk_ros1_inhibitor_lorlatinib_granted_breakthrough_therapy_designation_from_fda_for_alk_positive_metastatic_non_small_cell_lung_cancer
49. LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC - PMC - PubMed Central, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10106481/
50. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced ..., accessed August 8, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.18.02236
51. Study Details | Lorlatinib Combinations in Lung Cancer - ClinicalTrials.gov, accessed August 8, 2025, https://clinicaltrials.gov/study/NCT04292119
52. Lorbrena (lorlatinib) FDA Approval History - Drugs.com, accessed August 8, 2025, https://www.drugs.com/history/lorbrena.html
53. Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC, accessed August 8, 2025, https://jhoponline.com/issue-archive/2021-issues/april-2021-vol-10-no-2/lorbrena-now-fda-approved-for-first-line-treatment-of-metastatic-nsclc
54. EMA Recommends Granting a Conditional Marketing Authorisation for Lorlatinib ESMO PRESS RELEASE - Filippo De Marinis, accessed August 8, 2025, https://www.filippodemarinis.it/public/EMA%20CHMP%20for%20Lorlatinib%20in%20ALK+.pdf
55. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden - PubMed Central, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10232573/
56. European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer | Pfizer, accessed August 8, 2025, https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-lorviquar-lorlatinib-first
57. Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis - PMC - PubMed Central, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8345181/
58. Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems... | Oncotarget, accessed August 8, 2025, https://www.oncotarget.com/article/27875/text/
59. Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis - MDPI, accessed August 8, 2025, https://www.mdpi.com/1422-0067/24/3/2242
60. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor–naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis - ResearchGate, accessed August 8, 2025, https://www.researchgate.net/publication/352515945_Comparison_of_lorlatinib_alectinib_and_brigatinib_in_ALK_inhibitor-naiveuntreated_ALK-positive_advanced_non-small-cell_lung_cancer_a_systematic_review_and_network_meta-analysis
61. First-line ALK inhibitors in treatment-naive advanced ALK rearranged non-small cell lung cancer: systematic review and network meta-analysis, accessed August 8, 2025, https://pcm.amegroups.org/article/view/7628/html
62. (PDF) Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis - ResearchGate, accessed August 8, 2025, https://www.researchgate.net/publication/367349202_Comparative_Efficacy_of_ALK_Inhibitors_for_Treatment-Naive_ALK-Positive_Advanced_Non-Small_Cell_Lung_Cancer_with_Central_Nervous_System_Metastasis_A_Network_Meta-Analysis
63. Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials - MDPI, accessed August 8, 2025, https://www.mdpi.com/2072-6694/16/13/2457